BR0311141A - Interação sinergìstica de abacavir e alovudine - Google Patents

Interação sinergìstica de abacavir e alovudine

Info

Publication number
BR0311141A
BR0311141A BR0311141-5A BR0311141A BR0311141A BR 0311141 A BR0311141 A BR 0311141A BR 0311141 A BR0311141 A BR 0311141A BR 0311141 A BR0311141 A BR 0311141A
Authority
BR
Brazil
Prior art keywords
alovudine
abacavir
synergistically
interaction
treatment
Prior art date
Application number
BR0311141-5A
Other languages
English (en)
Inventor
G Ran Mordh
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0202022A external-priority patent/SE0202022D0/xx
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of BR0311141A publication Critical patent/BR0311141A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)

Abstract

"INTERAçãO SINERGìSTICA DE ABACAVIR E ALOVUDINE". Uma preparação farmacêutica compreendendo uma combinação sinergística de abacavir e alovudine e um carreador farmacêutica para a mesma. Uso de abacavir e alovudine juntos para o tratamento de HIV multi - resistente, onde o uso compreende administração simultânea, combinada ou seq³encial de alovudine e abacavir.
BR0311141-5A 2002-06-27 2003-06-24 Interação sinergìstica de abacavir e alovudine BR0311141A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0202022A SE0202022D0 (sv) 2002-06-27 2002-06-27 Synergistic interaction of abacavir and alovudine
EP02024744 2002-11-06
PCT/SE2003/001100 WO2004002433A1 (en) 2002-06-27 2003-06-24 Synergistic interaction of abacavir and alovudine

Publications (1)

Publication Number Publication Date
BR0311141A true BR0311141A (pt) 2005-06-07

Family

ID=30001852

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311141-5A BR0311141A (pt) 2002-06-27 2003-06-24 Interação sinergìstica de abacavir e alovudine

Country Status (19)

Country Link
US (1) US20060084627A1 (pt)
EP (1) EP1536800B1 (pt)
JP (1) JP2005533870A (pt)
KR (1) KR20050013628A (pt)
CN (1) CN1302779C (pt)
AT (1) ATE314851T1 (pt)
AU (1) AU2003239088B2 (pt)
BR (1) BR0311141A (pt)
CA (1) CA2481890A1 (pt)
DE (1) DE60303131T2 (pt)
ES (1) ES2254941T3 (pt)
HK (1) HK1079981B (pt)
IL (1) IL164921A0 (pt)
MX (1) MXPA04012754A (pt)
NO (1) NO20050445L (pt)
NZ (1) NZ535817A (pt)
PL (1) PL373758A1 (pt)
RU (1) RU2320347C2 (pt)
WO (1) WO2004002433A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087169A1 (en) * 2003-03-27 2004-10-14 Boehringer Ingelheim International Gmbh Antiviral combination of nevirapine and a further antiretroviral compound
GB0608876D0 (en) 2006-05-05 2006-06-14 Medivir Ab Combination therapy
MX356891B (es) * 2010-01-27 2018-06-19 Viiv Healthcare Co Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapéuticos.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8602981D0 (sv) * 1986-07-04 1986-07-04 Astra Laekemedel Ab Novel medicinal use
US5446029A (en) * 1986-07-04 1995-08-29 Medivir Ab Anti-retroviral activity of 2',3'-dideoxy-3'-fluoronucleosides
GB8719877D0 (en) * 1987-08-22 1987-09-30 Wellcome Found Antiviral compounds
NZ229453A (en) * 1988-06-10 1991-08-27 Univ Minnesota & Southern Rese A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents
SE464168B (sv) * 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
DK1431304T3 (en) * 1998-08-10 2015-03-02 Novartis Ag Beta - L-2'-deoxynucleosides for the treatment of hepatitis B
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
PT1143976E (pt) * 1999-01-22 2006-09-29 Univ Emory Beta-d-2' , 3'-didesidro-2' , 3'-didesoxi-5-fluorocitidina para utilizacao no tratamento de infeccoes por vih
US6514979B1 (en) * 1999-03-03 2003-02-04 University Of Maryland Biotechnology Institute Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor
US20030113292A1 (en) * 2000-06-02 2003-06-19 Esser Klaus M Methods of treating viral diseases with il-18 and il-18 combinations

Also Published As

Publication number Publication date
PL373758A1 (en) 2005-09-05
AU2003239088B2 (en) 2006-11-02
DE60303131T2 (de) 2006-07-20
ES2254941T3 (es) 2006-06-16
KR20050013628A (ko) 2005-02-04
CN1665509A (zh) 2005-09-07
NO20050445L (no) 2005-01-26
CN1302779C (zh) 2007-03-07
EP1536800A1 (en) 2005-06-08
EP1536800B1 (en) 2006-01-04
US20060084627A1 (en) 2006-04-20
HK1079981A1 (en) 2006-04-21
WO2004002433A1 (en) 2004-01-08
DE60303131D1 (de) 2006-03-30
RU2320347C2 (ru) 2008-03-27
AU2003239088A1 (en) 2004-01-19
JP2005533870A (ja) 2005-11-10
MXPA04012754A (es) 2005-03-23
NZ535817A (en) 2006-11-30
RU2005101874A (ru) 2005-06-27
ATE314851T1 (de) 2006-02-15
CA2481890A1 (en) 2004-01-08
IL164921A0 (en) 2005-12-18
WO2004002433A8 (en) 2004-05-06
HK1079981B (zh) 2007-10-12

Similar Documents

Publication Publication Date Title
AR035500A1 (es) Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina.
ATE309798T1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
DK1259240T3 (da) Midler, såsom nikotinamid eller CADPR, til behandling af hudsygdomme
EA200602047A1 (ru) Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака
DK1365808T3 (da) Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
AR032293A1 (es) Estuche farmaceutico
HK1068606A1 (en) Novel aminobenzoephenones
ATE287264T1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
DE60336225D1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
CO5700723A2 (es) Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca
HRP20070291T3 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
TR200102512T2 (tr) Tüm ruhsal bozukluklar, adaptasyon bozuklukları ve çeşitli kaygı-depresyon bozukluklarının tedavisinde ya da önlenmesinde yararlı tıbbi ürünlerin hazırlanması için saredutan ve onun farmasötik olarak kabul edilebilir tuzlarının kullanımı.
NO20050445L (no) Synergistisk interaksjon mellom abacavir og alovudin
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
HUP0204208A2 (hu) Pruritus kezelésére szolgáló külsőleges gyógyszerkészítmény
CA2385755A1 (en) Prevention of colorectal cancer
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
AU2003281468A1 (en) P-glycoprotein inhibitor comprising octilonium bromide as an effective ingredient
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
ATE261732T1 (de) Pharmazeutische zusammensetzung, umfassend eukalyptus- und orangenöl
AU2002225097A1 (en) Novel therapeutic use of a thienylcyclohexylamine derivative
DE50307169D1 (de) ORALE VAKZINIERUNG MIT DEM TUMOR-ANTIGEN-MIMOTOP Gln-Met-Trp-Ala-Pro-Gln-Trp-Gly-Pro-Asp

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010.